About

DeepMed’s team is one of the pioneers in machine learning analysis of histopathology images with award winning results. DeepMed has been awarded in excess of £1.4m of non-diluting funding to develop AI-powered decision support systems in collaboration with the UK-NHS. As a result, DeepMed developed all the necessary know-how, which is now utilising for providing AI-development for health care as a service.

Solution & Product

DeepMed has engaged with multiple companies from the diagnostic sector and from the cell & gene therapy sector offering its know-how to develop AI-powered solutions.

Innovation & Scalability

The foundational expertise developed by the company to the current day has paved the way for DeepMed to expand its services, offering the development of AI-driven healthcare solutions as a scalable, customizable service model. Engaging with companies across diagnostics and cell & gene therapy sectors, DeepMed’s adaptable approach ensures that its cutting-edge AI technologies can be rapidly tailored to meet diverse needs, making it an indispensable partner for scalable healthcare advancements.

Traction & achievements

In 2017 we received Phase-1 funding from the NHS(SBRI) (£150,000) to develop a proof-of-concept system for detecting metastatic regions on lymph nodes from breast cancer patients. In 2018 we received Phase-2 funding from the NHS(SBRI) (£1,000,000) to further develop our Phase-1 deliverable. In 2018 we were also selected to join the NVIDIA Inception Program for promising AI-startups. In 2019, our metastasis detection model for Breast Cancer scored at the time of submission the 5th best position in the world in the international competition Camelyon-17 achieving 90.52% agreement with world-expert. In 2022 we won the 12th NBG seeds competition.

Team & Why Us

DeepMed’s growth strategy is centered on expanding partnerships within the healthcare and biotech industries, leveraging its proven expertise in AI. By targeting collaborations with diagnostics and cell & gene therapy companies, DeepMed aims to broaden its client base, providing tailored AI solutions that integrate seamlessly into diverse therapeutic and diagnostic workflows. Additionally, DeepMed focuses on increasing its investment in R&D to stay at the forefront of AI innovation, ensuring its solutions address emerging healthcare challenges. With a flexible service model that allows for custom AI development, DeepMed is positioned to scale rapidly by adapting its technology to meet specific partner needs, fostering long-term relationships and sustained revenue growth. This strategic approach allows DeepMed to continuously refine its offerings and solidify its position as a leader in AI-driven healthcare solutions.

Funding Needs

The company seeks to raise seed funding to expand its service-providing business to the UK and European market.